RLAY

Relay Therapeutics Inc

RLAY, USA

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins; and RLY-1013, a degrader of estrogen receptor alpha. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

https://www.relaytx.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RLAY
stock
RLAY

Relay Therapeutics (RLAY): Revisiting Valuation After a Sharp Rebound in 2024 Yahoo Finance

Read more →
RLAY
stock
RLAY

Meme Stocks: Is RLAY stock recession proof - July 2025 Outlook & Capital Efficiency Focused Strategies moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$13.9

Analyst Picks

Strong Buy

6

Buy

5

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

High

2.28

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-12.20 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-11.07 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.10

Low 1

High 0.3

Investors

* Institutions hold a combined 99.25% of the total shares of Relay Therapeutics Inc

1.

SB INVESTMENT ADVISERS (UK) LTD

(16.1851%)

since

2025/06/30

2.

BlackRock Inc

(8.0937%)

since

2025/06/30

3.

Point72 Asset Management, L.P.

(7.7986%)

since

2025/06/30

4.

COMMODORE CAPITAL LP

(7.7431%)

since

2025/06/30

5.

Casdin Capital, LLC

(6.6113%)

since

2025/06/30

6.

Vanguard Group Inc

(5.4404%)

since

2025/06/30

7.

Bellevue Group AG

(4.774%)

since

2025/06/30

8.

TANG CAPITAL MANAGEMENT LLC

(4.6795%)

since

2025/06/30

9.

BB Biotech AG Ord

(4.2776%)

since

2024/12/31

10.

State Street Corp

(3.0177%)

since

2025/06/30

11.

Vanguard Total Stock Mkt Idx Inv

(2.999%)

since

2025/07/31

12.

JPMorgan Chase & Co

(2.5163%)

since

2025/06/30

13.

Nextech Invest, Ltd.

(2.2309%)

since

2025/06/30

14.

Geode Capital Management, LLC

(1.8732%)

since

2025/06/30

15.

iShares Russell 2000 ETF

(1.8727%)

since

2025/08/31

16.

Kynam Capital Management, LP

(1.6745%)

since

2025/06/30

17.

T. Rowe Price Associates, Inc.

(1.6681%)

since

2025/06/30

18.

Dimensional Fund Advisors, Inc.

(1.6179%)

since

2025/06/30

19.

MPM Oncology Impact Management LP

(1.324%)

since

2025/06/30

20.

SPDR® S&P Biotech ETF

(1.2858%)

since

2025/08/31

21.

Goldman Sachs Group Inc

(1.1224%)

since

2025/06/30

22.

Millennium Management LLC

(1.0848%)

since

2025/06/30

23.

Alphabet Inc

(0.9099%)

since

2025/06/30

24.

Renaissance Technologies Corp

(0.8748%)

since

2025/06/30

25.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8322%)

since

2025/07/31

26.

Fidelity Small Cap Index

(0.7715%)

since

2025/06/30

27.

US Small-Cap Growth II Equity Comp

(0.7265%)

since

2025/06/30

28.

iShares Russell 2000 Value ETF

(0.6853%)

since

2025/08/31

29.

BlackRock Advantage Small Cap Core Instl

(0.6194%)

since

2025/07/31

30.

iShares Biotechnology ETF

(0.4513%)

since

2025/08/31

31.

Fidelity Extended Market Index

(0.4228%)

since

2025/07/31

32.

T. Rowe Price Health Sciences

(0.418%)

since

2025/07/31

33.

DFA US Micro Cap I

(0.3946%)

since

2025/07/31

34.

Schwab US Small-Cap ETF™

(0.3729%)

since

2025/08/30

35.

Vanguard Russell 2000 ETF

(0.3666%)

since

2025/07/31

36.

T. Rowe Price New Horizons

(0.3621%)

since

2025/07/31

37.

Vanguard Strategic Small-Cap Equity Inv

(0.3121%)

since

2025/06/30

38.

DFA US Targeted Value I

(0.2992%)

since

2025/07/31

39.

State St Russell Sm Cap® Indx SL Cl I

(0.2717%)

since

2025/08/31

40.

Dimensional US Targeted Value ETF

(0.2672%)

since

2025/08/29

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.43

EPS Estimate

-0.418

EPS Difference

-0.012

Surprise Percent

-2.8708%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.